GE HealthCare Technologies (MEX:GEHC) Debt-to-EBITDA : 3.50 (As of Mar. 2026) — 34% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:GEHC GE HealthCare Technologies Inc MEX:GEHC
63 GF Score
Price MXN1,100.00
GF Value MXN1,491.85
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is GE HealthCare Technologies Debt-to-EBITDA?

GE HealthCare Technologies MEX:GEHC 63 Debt-to-EBITDA is 3.50 as of Mar. 2026, which is 34% above its 10-year median of 2.62. GuruFocus rates MEX:GEHC with a GF Score™ of 63/100 and a GF Value™ of MXN1,491.85 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 467 Medical Devices & Instruments companies, GE HealthCare Technologies ranks worse than 69.38% on this metric.

Debt-to-EBITDA measures a company's ability to pay off its debt.

GE HealthCare Technologies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was MXN2,507 Mil. GE HealthCare Technologies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was MXN188,225 Mil. GE HealthCare Technologies's annualized EBITDA for the quarter that ended in Mar. 2026 was MXN54,459 Mil. GE HealthCare Technologies's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2026 was 3.50.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for GE HealthCare Technologies's Debt-to-EBITDA or its related term are showing as below:

MEX:GEHC' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.12   Med: 2.62   Max: 2.94
Current: 2.94

During the past 7 years, the highest Debt-to-EBITDA Ratio of GE HealthCare Technologies was 2.94. The lowest was 0.12. And the median was 2.62.

MEX:GEHC's Debt-to-EBITDA is ranked worse than
69.38% of 467 companies
in the Medical Devices & Instruments industry
Industry Median: 1.6 vs MEX:GEHC: 2.94

GE HealthCare Technologies  (MEX:GEHC) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


GE HealthCare Technologies Debt-to-EBITDA Related Terms


GE HealthCare Technologies Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for GE HealthCare Technologies's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GE HealthCare Technologies Debt-to-EBITDA Chart

GE HealthCare Technologies Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-EBITDA
Get a 7-Day Free Trial 0.12 2.67 2.81 2.56 2.76

GE HealthCare Technologies Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.45 3.07 2.98 2.44 3.50

MEX:GEHC vs DXCM, STE, ZBH: Debt-to-EBITDA Comparison

For the Medical Devices subindustry, GE HealthCare Technologies's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GE HealthCare Technologies Debt-to-EBITDA vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, GE HealthCare Technologies's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where GE HealthCare Technologies's Debt-to-EBITDA falls into.


MEX:GEHC
63GF Score
GE HealthCare Technologies Inc MEX:GEHC
Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GE HealthCare Technologies Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

GE HealthCare Technologies's Debt-to-EBITDA for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(11559.659 + 176833.98) / 68169.58
=2.76

GE HealthCare Technologies's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2026 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(2506.545 + 188225.323) / 54458.756
=3.50

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.

Frequently Asked Questions Learn more about Debt-to-EBITDA →
What does a Debt-to-EBITDA of 3.50 mean?
GE HealthCare Technologies (MEX:GEHC) has a Debt-to-EBITDA of 3.50 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on GE HealthCare Technologies. This is 34% above median its historical median of 2.62. Over the past decade, GE HealthCare Technologies' Debt-to-EBITDA has ranged from 0.12 to 2.94. According to the industry distribution chart, GE HealthCare Technologies ranks #324 out of 467 companies in the Medical Devices & Instruments industry, placing it in the top 69.4%.
Is GE HealthCare Technologies' Debt-to-EBITDA too high?
GE HealthCare Technologies' current Debt-to-EBITDA of 3.50 is 34% above median its 10-year median of 2.62. Over the past 10 years, this metric has ranged from a low of 0.12 to a high of 2.94. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.60. GE HealthCare Technologies' value of 3.50 is 118.8% above this industry median. Based on the distribution chart, GE HealthCare Technologies ranks #324 out of 467 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, GE HealthCare Technologies has a GF Score™ of 63/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does GE HealthCare Technologies' Debt-to-EBITDA compare to DXCM and STE?
According to the Medical Devices & Instruments industry distribution chart, GE HealthCare Technologies ranks #324 out of 467 companies for Debt-to-EBITDA. This places GE HealthCare Technologies in the lower half of its industry. The industry median Debt-to-EBITDA is 1.60. GE HealthCare Technologies' value of 3.50 is 118.8% above this benchmark. Historically, GE HealthCare Technologies' own Debt-to-EBITDA has ranged from 0.12 to 2.94 over the past decade. While the company's 10-year median is 2.62 vs. the industry median of 1.60, GE HealthCare Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.60, based on 467 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GE HealthCare Technologies's current Debt-to-EBITDA of 3.50 is 118.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on GE HealthCare Technologies. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GE HealthCare Technologies's current Debt-to-EBITDA is 3.50, which is 34% above median its own 10-year median of 2.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GE HealthCare Technologies stock overvalued right now?
Based on GuruFocus' analysis, GE HealthCare Technologies (MEX:GEHC) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN1,491.85, compared to a current price of MXN1,100.00 — trading 26.3% below its estimated fair value. The current Debt-to-EBITDA is 3.50, which is 34% above median its 10-year median of 2.62 and 118.8% above the Medical Devices & Instruments industry median of 1.60. GE HealthCare Technologies' overall GF Score™ is 63/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For GE HealthCare Technologies (MEX:GEHC), the current Debt-to-EBITDA is 3.50 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GE HealthCare Technologies (MEX:GEHC) Overvalued in 2026?

Based on GuruFocus' analysis, GE HealthCare Technologies stock appears to be undervalued. The current stock price of MXN1,100.00 is trading 26.3% below its estimated GF Value™ of MXN1,491.85. GuruFocus considers GE HealthCare Technologies to be Modestly Undervalued.

Key valuation signals for MEX:GEHC:

  • Debt-to-EBITDA: 3.50 (34% above median its 10-year median of 2.62)
  • GF Value™: MXN1,491.85 vs. price of MXN1,100.00 (26.3% below fair value)
  • GF Score™: 63/100 with 4 warning signs
  • Industry Position: 118.8% above the Medical Devices & Instruments median (#324 of 467)

No single metric tells the full story. See the MEX:GEHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


GE HealthCare Technologies Business Description

Address 500 West Monroe Street, Chicago, IL, USA, 60661
GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (45% of revenue), advanced visualization solutions (26%), patient care solutions (15%), and pharmaceutical diagnostics (14%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 46%, 26%, 11%, and 17%, respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (about one-third of revenue), pharmaceutical diagnostics (about 10%-15%), and digital solutions (just over 5%).
63GF Score

Get the complete analysis for MEX:GEHC

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,100.00
Price
MXN1,491.85
GF Value